Story · Medicine & Biotech

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer

1 outlet · first reported by MHRA (UK) 10h ago

Coverage, in order

  1. 10h ago
    MHRA (UK) UK indie
    MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer

    The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC).

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.